Clinical Trials /

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

NCT01160211

Description:

A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).

Related Conditions:
  • Breast Carcinoma
Recruiting Status:

Active, not recruiting

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
  • Official Title: A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2+ Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies

Clinical Trial IDs

  • ORG STUDY ID: 114299
  • NCT ID: NCT01160211

Conditions

  • Neoplasms, Breast

Interventions

DrugSynonymsArms
lapatinibLapatinib plus trastuzumab plus aromatase inhibitor
trastuzumabtrastuzmab plus aromatase inhibitor
Aromatase inhibitorlapatinib plus aromatase inhibitor
lapatiniblapatinib plus aromatase inhibitor

Purpose

A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).

Detailed Description

      This is a Phase III, randomized, open-label, multi-center, three arm study of lapatinib plus
      trastuzumab plus an aromatase inhibitor (AI), trastuzumab plus an AI, or lapatinib plus an AI
      to evaluate the efficacy and safety of these regimens as first- or second-line therapy in
      postmenopausal subjects with hormone receptor positive (HR+), HER2-positive metastatic breast
      cancer (MBC) who have received prior trastuzumab and endocrine therapies. Eligible subjects
      will be postmenopausal; have tumors that are ER and/or PgR positive and HER2-positive; have
      Stage IV metastatic breast cancer. The primary objective is to demonstrate superiority of
      lapatinib/trastuzumab/AI combination versus (vs.) trastuzumab/AI combination for progression
      free survival. The secondary objectives are to evaluate progression free survival in
      trastuzumab/AI vs. lapatinib/AI and trastuzumab/lapatinib/AI vs. lapatinib/AI, overall
      survival, overall response rate, clinical benefit rate, the safety and tolerability of all
      three treatment groups (lapatinib plus trastuzumab plus an AI, trastuzumab plus an AI, or
      lapatinib plus an AI), and quality of life status relative to baseline.
    

Trial Arms

NameTypeDescriptionInterventions
Lapatinib plus trastuzumab plus aromatase inhibitorExperimentalExperimental
  • lapatinib
  • trastuzumab
  • Aromatase inhibitor
trastuzmab plus aromatase inhibitorActive ComparatorActive Comparator
  • trastuzumab
  • Aromatase inhibitor
lapatinib plus aromatase inhibitorActive ComparatorActive Comparator
  • Aromatase inhibitor
  • lapatinib

Eligibility Criteria

        Inclusion Criteria

        Subjects eligible for enrollment in the study must meet all of the following criteria:

          1. Signed written informed consent. In Korea and Japan, subjects who are between >=18 and
             <20 years of age must also have a legal representative sign the written informed
             consent.

          2. Post-menopausal female subjects >=18 years of age. Post-menopausal as defined by any
             of the following:

               -  Subjects at least 60 years of age.

               -  Subjects under 60 years of age and amenorrhic for at least 12 consecutive months
                  AND follicle-stimulating hormone (FSH) and estradiol levels in postmenopausal
                  range (utilizing ranges from the local laboratory facility).

               -  Prior bilateral oophorectomy.

               -  Prior radiation castration with amenorrhea for at least 6 months

          3. Subjects must have a history of histologically confirmed breast cancer, with a
             clinically confirmed diagnosis of metastatic disease [confirmed by histology, cytology
             or other clinical means (e.g. CT, MRI)]. Subjects may have either measurable or
             non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

          4. Tumors that are ER+ and/or PgR+ by local laboratory

          5. Documentation of HER2 overexpression or gene amplification, in the invasive component
             of either the primary tumor or metastatic disease site as defined as:

               -  3+ by Immunohistochemistry (IHC) and/or

               -  HER2/neu gene amplification by fluorescence, chromogenic or silver in situ
                  hybridization [FISH, CISH or SISH; >6 HER2/neu gene copies per nucleus or a FISH,
                  CISH or SISH test ratio (HER2 gene copies to chromosome 17 signals) of ≥2.0]

          6. Subject must have received at least one prior regimen containing trastuzumab in
             combination with chemotherapy for breast cancer:.

               -  Subject has ONLY received prior trastuzumab in combination with chemotherapy as
                  neoadjuvant and/or adjuvant treatment. OR

               -  Subject has received ONE prior trastuzumab-containing regimen for metastatic
                  disease (and has progressed), and may or may not have received prior trastuzumab
                  in combination with chemotherapy as neoadjuvant and/or adjuvant treatment.

          7. Subject must have received prior endocrine therapy (such as aromatase inhibitors or
             selective estrogen receptor modulators). 8. Subjects who have a life expectancy of > 6
             months as assessed by the treating investigator

        9. Subjects must have baseline Left Ventricular Ejection Fraction (LVEF) ≥50% measured by
        echocardiography (ECHO) or multi-gated acquisition scan (MUGA) 10. Subject must have an
        ECOG performance status of 0-1 11. All prior treatment related toxicities must be CTCAE
        (Version 4.0) ≤ Grade 1 at the time of randomization 12. Completion of screening
        assessments 13. Adequate baseline organ function. 14. Subjects must meet all of the
        following criteria:

          -  QTc <450msec or

          -  QTc <480msec for subjects with bundle branch block The QTc is the QT interval
             corrected for heart rate according to either Bazett's formula (QTcB) or to
             Fridericia's formula (QTcF), machine or manual over read, for males and females. The
             specific formula that will be used in a protocol should be determined prior to
             initiation of the study, and the formula used to determine inclusion and
             discontinuation should be the same throughout the study. The QTc should be based on
             single or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a
             brief recording period

        Exclusion criteria:

          1. History of another malignancy. Exception: Subjects who have been disease-free for 5
             years, or subjects with a history of completely resected non-melanoma skin cancer or
             successfully treated in situ carcinoma are eligible.

          2. Subjects with extensive symptomatic visceral disease including hepatic involvement and
             pulmonary lymphangitic spread of tumor, or the disease is considered by the
             investigator to be rapidly progressing or life threatening (subjects who are intended
             for chemotherapy)

          3. Serious cardiac illness or medical condition including but not confined to:

               -  Uncontrolled arrhythmias

               -  Uncontrolled or symptomatic angina

               -  History of congestive heart failure (CHF)

               -  Documented myocardial infarction <6 months from study entry

          4. Known history of, or clinical evidence of, central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis

          5. Have acute or currently active/requiring anti-viral therapy hepatic or biliary disease
             (with the exception of subjects with Gilbert's syndrome, asymptomatic gallstones,
             liver metastases or stable chronic liver disease per investigator assessment)

          6. Have a concurrent disease or condition that may interfere with study participation, or
             any serious medical disorder that would interfere with the subject's safety (for
             example, active or uncontrolled infection or any psychiatric condition prohibiting
             understanding or rendering of informed consent)

          7. Have any clinically significant gastrointestinal abnormalities that may alter
             absorption such as malabsorption syndrome or major resection of the stomach or bowels

          8. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to any of the study agents or their excipients that, in the opinion
             of the Investigator or GSK medical monitor, contraindicates their participation

          9. Any prohibited medication.

         10. Administration of an investigational drug within 30 days or 5 half-lives, whichever is
             longer, preceding the first dose of study treatment.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:Female
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression free survival (PFS) of lapatinib/trastuzumab/aromatase inhibitor (AI) combination vs. trastuzumab/AI combination
Time Frame:approximately 6 years
Safety Issue:
Description:

Secondary Outcome Measures

Measure:Progression free survival (PFS) of trastuzumab/AI vs. lapatinib/AI and trastuzumab/lapatinib/AI vs. lapatinib/AI
Time Frame:approximately 6 years
Safety Issue:
Description:
Measure:Overall survival (OS) of lapatinib/trastuzumab/AI vs. trastuzumab/AI and lapatinib/AI vs. trastuzumab/AI
Time Frame:approximately 6 years
Safety Issue:
Description:
Measure:Overall response rate (complete or partial response), time to response, and duration of response in lapatinib/trastuzumab/AI vs. trastuzumab/AI and lapatinib/AI vs. trastuzumab/AI
Time Frame:approximately 6 years
Safety Issue:
Description:
Measure:Clinical benefit (complete response, partial response, or stable disease for at least 6 months) of lapatinib/trastuzumab/AI vs. trastuzumab/AI and lapatinib/AI vs. trastuzumab/AI
Time Frame:approximately 6 years
Safety Issue:
Description:
Measure:Safety and tolerability of all three treatment groups (lapatinib/ trastuzumab/ AI, trastuzumab/ AI, or lapatinib/AI)
Time Frame:approximately 6 years
Safety Issue:
Description:
Measure:Changes in the quality of life (QoL) status relative to baseline of lapatinib/trastuzumab/AI vs. trastuzumab/AI and lapatinib/AI vs. trastuzumab/AI
Time Frame:approximately 6 years
Safety Issue:
Description:

Details

Phase:Phase 3
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:Novartis Pharmaceuticals

Trial Keywords

  • 1st line MBC
  • MBC
  • hormone receptor positive
  • lapatinib
  • trastuzumab
  • HER2 positive
  • aromatase inhibitor

Last Updated

October 16, 2017